Inhaled therapy receives FDA breakthrough designation for non-cystic fibrosis bronchiectasis

The FDA granted breakthrough therapy designation to colistimethate sodium powder for nebulization solution to reduce pulmonary exacerbations in adults with non-cystic fibrosis bronchiectasis and Pseudomonas aeruginosa.
Colistimethate sodium powder for nebulization solution (CMS I-neb, Zambon) is being developed as a potential first-in-class inhaled therapy for adults with non-cystic fibrosis bronchiectasis colonized with P. aeruginosa. CMS I-neb delivers targeted drug concentrations directly to the disease site to minimize systemic exposure that can cause toxicity and adverse events, according

The FDA granted breakthrough therapy designation to colistimethate sodium powder for nebulization solution to reduce pulmonary exacerbations in adults with non-cystic fibrosis bronchiectasis and Pseudomonas aeruginosa.
Colistimethate sodium powder for nebulization solution (CMS I-neb, Zambon) is being developed as a potential first-in-class inhaled therapy for adults with non-cystic fibrosis bronchiectasis colonized with P. aeruginosa. CMS I-neb delivers targeted drug concentrations directly to the disease site to minimize systemic exposure that can cause toxicity and adverse events, according